$ALT News
Last published 16h ago
- 16h agoALTAltimmune, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 16h agoALTAltimmune Announces Third Quarter 2026 Financial Results and Business UpdateGlobeNewswireGlobal PERFORMA Phase 3 trial in MASH progressing as planned
- 17h agoALTAltimmune Announces Publication of IMPACT Phase 2b 48-Week Data in MASH in The Lancet Gastroenterology & HepatologyGlobeNewswireSignificant reductions across non-invasive measures of liver fat, inflammation and fibrosis observed at 48 weeks of pemvidutide treatment, with generally favorable tolerability profile
- 3d agoALTAltimmune Presents Positive Late-Breaking Pemvidutide Data at AASLD The Liver Meeting® 2026 in Patients with Alcohol Use DisorderGlobeNewswireResults from RECLAIM Phase 2 study show treatment with pemvidutide led to significant reduction in heavy drinking days and improved outcomes on other key clinical measures in patients with AUD; generally favorable tolerability profile
- 3d agoALTAltimmune Presents Positive Late-Breaking Pemvidutide Data at AASLD The Liver Meeting® 2026 in Patients with Alcohol Use DisorderGlobeNewswireResults from RECLAIM Phase 2 study show treatment with pemvidutide led to significant reduction in heavy drinking days and improved outcomes on other key clinical measures in patients with AUD; generally favorable
- 1w agoALTAltimmune Announces Data from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder Selected as Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2026GlobeNewswireFirst presentation at a scientific conference of key data from RECLAIM, a multicenter Phase 2 trial of a balanced 1:1 glucagon/GLP-1 receptor agonist in alcohol use disorder (AUD) Presentation to take place on Monday,
- 1w agoPNGAFMBXKLRAALT+1Federal Peptide Policy Shift Could Ignite a New Wave Of Growth Across the $164 Billion Peptide MarketGlobeNewswireNEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- The federal government's October 30, 2026, decision could be a big deal for the peptide industry. HHS has signaled that it does not intend to pursue enforcement action
- 1w agoALTAltimmune to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026GlobeNewswireMORRISTOWN, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company advancing pemvidutide, an investigational balanced 1:1 glucagon/GLP-1 receptor agonist, in serious liver
- 2w agoALTPTHSAltimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic EvolutionGlobeNewswireBoard appointments align with successful transition to late-stage clinical Company developing pemvidutide as a differentiated liver franchise with multiple potential indications As part of this transition, John M.
- 3w agoALTAltimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026GlobeNewswireClinical highlights from the IMPACT Phase 2b study of pemvidutide in MASH demonstrated improvements in liver fibrosis and inflammation with generally favorable gastrointestinal tolerability Oral presentation to feature
- 1mo agoALTSTIFEL 2026 VIRTUAL CARDIOMETABOLIC FORUM - ALTIMMUNE INCEarnings Call TranscriptsHi, good morning, everyone, and welcome to the Altimmune Session. I'm Annabelle Samimi, Biopharmaceutical Analyst here at Stiefel. We're pleased to have with us today CEO Jerome Durso, Chief Medical Officer Christoph Arb
- 1mo agoALTSTIFEL 2026 VIRTUAL CARDIOMETABOLIC FORUM - ALTIMMUNE INCEarnings Call TranscriptsHi, good morning, everyone, and welcome to the Altimmune Session. I'm Annabelle Samimi, Biopharmaceutical Analyst here at Stiefel. We're pleased to have with us today CEO Jerome Durso, Chief Medical Officer Christoph Arb
- 2mo agoALTWells Fargo 21st Annual Healthcare Conference - ALTIMMUNE INCEarnings Call TranscriptsAwesome. Thank you very much for joining us today. My name is Mohit Bansal. I'm one of the biotech and pharma analysts at Wells Fargo, and I'm very happy to have Altimmune Management team with us today, so we are joined
- 2mo agoALTWELLS FARGO 21ST ANNUAL HEALTHCARE CONFERENCE - ALTIMMUNE INCEarnings Call TranscriptsAwesome. Thank you very much for joining us today. My name is Mohit Bansal. I'm one of the biotech and pharma analysts at Wells Fargo, and I'm very happy to have Altimmune Management team with us today, so we are joined
- 2mo agoALTAltimmune to Participate in the Wells Fargo 21st Annual Healthcare ConferenceGlobeNewswireGAITHERSBURG, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that
- 3mo agoALTAltimmune Second Quarter 2026 Earnings Conference Call - ALTIMMUNE INCEarnings Call TranscriptsGood morning, ladies and gentlemen. Welcome to the Altamunian Second Quarter 2026 Financial Results Conference Call. At this time, all participants are in listen-only mode. After this speaker's presentation, there will b
- 3mo agoALTAltimmune Announces Second Quarter 2026 Financial Results and Business UpdateGlobeNewswireInitiated global PERFORMA Phase 3 trial in MASH Reported positive topline data from RECLAIM Phase 2 trial in AUD Completed patient enrollment in RESTORE Phase 2 trial in ALD $519 million in cash, cash equivalents
- 3mo agoALTAltimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026GlobeNewswireGAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will
- 3mo agoALTAltimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASHGlobeNewswireGlobal registrational study designed to evaluate pemvidutide on fibrosis improvement, MASH resolution, and clinical outcomes Initiation marks advancement of Altimmune's lead program into late-stage development
- 3mo agoALTAltimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use DisorderGlobeNewswirePemvidutide 2.4 mg delivered a statistically significant and clinically meaningful reduction in heavy drinking days, the primary endpoint of the trial Important secondary endpoints were also met, including two-level
- 5mo agoALTPemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026GlobeNewswire"Best of EASL" oral presentation highlights meaningful reductions in triglycerides, cholesterol, and blood pressure, along with improvements in key metabolic risk factors PERFORMA Phase 3 trial to further evaluate the
- 5mo agoALTAltimmune to Participate in Upcoming Investor ConferencesGlobeNewswireGAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that
- 5mo agoALTNew IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026GlobeNewswireConcurrent improvement across key non-invasive tests underscores convergence of pemvidutide effects on MASH disease activity and fibrosis AI-based digital pathology analyses further demonstrate antifibrotic effects of
- 6mo agoABBVALTMRKSURNF+1Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market OpportunitiesGlobeNewswireAUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Obesity and type 2 diabetes mellitus (T2DM) rank among the most urgent and costly healthcare problems facing the world today, contributing
- 6mo agoALTAltimmune Announces First Quarter 2026 Financial Results and Business UpdateGlobeNewswireInitiation of PERFORMA Phase 3 MASH trial planned for second half 2026 $535 million in cash, cash equivalents and short-term investments as of April 30, 2026 Webcast to be held today at 8:30 a.m. ET GAITHERSBURG, Md.,
- 6mo agoALTAltimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026GlobeNewswireAbstract presenting 48-week IMPACT Phase 2b efficacy and safety data selected for inclusion in "Best of EASL 2026" by EASL Oral presentation will highlight further the 48-week IMPACT efficacy and safety data
- 6mo agoALTAltimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026GlobeNewswireGAITHERSBURG, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will
- 6mo agoALTAltimmune Announces Closing of $225 Million Oversubscribed Public Offering of SecuritiesGlobeNewswire$225 million funded at closing, with an additional $225 million warrant tranche Financing funds operations through anticipated Phase 3 MASH 52-week data readout Financing was led by Deep Track Capital, with
- 6mo agoALTAltimmune Announces Pricing of $225 Million Oversubscribed Public Offering of SecuritiesGlobeNewswireGAITHERSBURG, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced the pricing
- 6mo agoALTAltimmune Announces Proposed Underwritten Public Offering of SecuritiesGlobeNewswireGAITHERSBURG, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced it has
- 7mo agoVRTXCRSPALTARWRAnti-Aging Protein Research Takes a Step Forward with Cell CloningPR NewswireEquity-Insider.com — A protein called α-Klotho circulating in the bloodstream protects the brain, heart, kidneys, and the immune system....
- 8mo agoALTAltimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business UpdatesGlobeNewswireInitiation of Phase 3 MASH trial planned for 2026 Pemvidutide granted FDA Breakthrough Therapy Designation in MASH Topline data from RECLAIM Phase 2 trial of pemvidutide in alcohol use disorder (AUD) expected in third
- 8mo agoALTAltimmune to Participate in Upcoming Investor ConferencesGlobeNewswireGAITHERSBURG, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that
- 8mo agoALTAltimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026GlobeNewswireGAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will
- 9mo agoALTAltimmune Announces Closing of $75 Million Registered Direct Offering of Common StockGlobeNewswireGAITHERSBURG, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced the closing of its
- 9mo agoMNKDALTLCTXARWRLongevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell RestorationPR NewswireUSA News Group News Commentary – Global capital is officially rotating into "Longevity Infrastructure" which is now valued at a massive $27 trillion...
- 9mo agoALTAltimmune Announces Pricing of $75 Million Registered Direct Offering of Common StockGlobeNewswireGAITHERSBURG, Md., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced today that it has
- 10mo agoALTAltimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASHGlobeNewswireGAITHERSBURG, Md., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing therapies that address serious liver diseases, today announced the U.S. Food
- 10mo agoALTAltimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH TrialGlobeNewswireImprovements observed in key non-invasive markers of fibrosis across treatment arms versus placebo, with continued reductions from 24-week timepoint Additional weight loss from 24 to 48 weeks with 1.8 mg dose, without
- 11mo agoALTAltimmune Announces CEO Transition and Succession PlanGlobeNewswireJerry Durso, accomplished industry leader, to succeed Vipin Garg, Ph.D. as Chief Executive Officer Transition follows seven years of strong leadership by Dr. Garg GAITHERSBURG, Md., Dec. 01, 2025 (GLOBE NEWSWIRE) --
- 11mo agoALTAltimmune to Participate in the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswireGAITHERSBURG, Md., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases,
- 1y agoALTAltimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025GlobeNewswireAI-based digital pathology analysis provides high-resolution quantification of hepatic fibrosis and objective measurement of fibrosis improvement Pemvidutide demonstrated significant reductions in liver fibrosis and
- 1y agoALTAltimmune Announces Third Quarter 2025 Financial Results and Business UpdatesGlobeNewswire48-week Data from Phase 2b IMPACT Trial of Pemvidutide in MASH Expected Before Year End End-of-Phase 2 Meeting with FDA for MASH Program Scheduled in Fourth Quarter Executive Leadership Strengthened with Appointments
- 1y agoALTAltimmune to Participate in Two Upcoming Investor ConferencesGlobeNewswireGAITHERSBURG, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases,
- 1y agoALTAltimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use DisorderGlobeNewswireEnrollment completed ahead of schedule, underscoring strong interest from patient community in a potential new therapeutic option On track to complete the 24-week treatment period and announce topline results in 2026
- 1y agoALTAltimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025GlobeNewswireGAITHERSBURG, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases,
- 1y agoALTAltimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025GlobeNewswireOral presentation to highlight 24-week efficacy and safety data Poster to feature results of AI-based analyses of liver fibrosis reduction GAITHERSBURG, Md., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Altimmune,
- 1y agoALTFIVEFLYWHTZImportant Notice to Long-Term Shareholders of Altimmune, Inc. (NASDAQ: ALT); Five Below, Inc. (NASDAQ: FIVE); Flywire Corporation (NASDAQ: FLYW); and Hertz Global Holdings, Inc. (NASDAQ: HTZ): Grabar Law Office is Investigating Claims on Your BehalfGlobeNewswirePHILADELPHIA, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT): Grabar Law Office is investigating claims on behalf of shareholders of Altimmune, Inc. (NASDAQ:ALT). The investigation concerns whether
- 1y agoALTALT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AltimmuneGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Altimmune To Contact Him Directly To Discuss Their Options If you purchased or acquired securities
- 1y agoALTINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AltimmuneGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Altimmune To Contact Him Directly To Discuss Their Options If you suffered losses in Altimmune